peopleInnovationCareers RarePipelineCollaborationFinanceAdvance treatment Skip to main contentSkip to navigationSkip to search
Hansa Biopharma
HNSA (, %) SEK
Hansa Biopharma
Coffee and notepad

Press releases


8 Dec 2022, 08:00

· Idefirix[®] is granted full access and reimbursement in line with the indication approved by the European Medicines Agency (EMA).[1]
· The decision by the Italian Medicine Agency (AIFA) provides highly sensitized patients in Italy with the opportunity to receive Idefirix[®] to enable kidney transplantation.
28 Nov 2022, 18:00 | Regulatory
· Data readout demonstrates a significantly superior capacity of imlifidase to rapidly reduce levels of donor-specific antibodies (DSAs) compared to plasma exchange (standard of care) in the five days following the start of the treatment.
· A total of 30 patients have been randomized 2:1 to either imlifidase or plasma exchange with a six-month follow up period.[1]
20 Oct 2022, 08:00 | Regulatory

· Total Revenue of SEK 67m in the third quarter 2022
· Positive reimbursement decisions received in Poland and Scotland
· $70 million raised in non-dilutive financing
· Imlifidase included in ESOT guidelines published in Transplant International
30 Sep 2022, 08:00

· Award granted by internationally recognized Great Place to Work[®] institute.
· Certification based on company-wide survey completed by 99% of Hansa employees.
· Metrics related to trust in the company, credibility, pride and fairness, continue to be among those most highly rated by employees.
Load more
Coffee and notepad


Sign up to receive updates on the latest company news and filings

Choose type

Thank you. You will get an e-mail message to activate your subscription.